Eli Lilly Files Complaint with U.S. International Trade Commission Over Gemcitabine Patent Infringement

Summary

Eli Lilly & Company has filed a complaint with the U.S. International Trade Commission alleging that certain companies are infringing on its U.S. Patent No. 5,606,048, which covers gemcitabine and products containing the same, and requesting an investigation and potential exclusion order and cease and desist order.